International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 2, February 2026 **ijppr.humanjournals.com** ISSN: 2349-7203

Herbal Medicines and Evidence Based Phytotherapy in Breast Cancer

Rahul S Salunkhe[1], Gayatri P Holkar[2], Samiksha S Jagdale[3], Akshay Rajendra Kundale[4]*

KCT's Krishna College of Pharmacy, Karad, Maharashtra, India

Received: 27 December 2025 Revised: 10 January 2026 Accepted: 29 January 2026

ABSTRACT:

Breast cancer remains the most frequently diagnosed malignancy among women worldwide and continues to present major therapeutic challenges, including drug resistance, systemic toxicity, high treatment costs, and disease recurrence. Despite significant advances in surgery, chemotherapy, radiotherapy, hormonal therapy, and targeted therapies, limitations in efficacy and patient quality of life persist. In this context, herbal medicines and evidence-based phytotherapy have gained increasing attention as complementary and adjunct strategies in breast cancer management. Numerous plant-derived bioactive compounds, such as curcumin, genistein, resveratrol, and berberine, have demonstrated significant anticancer activities through multitarget mechanisms, including induction of apoptosis, inhibition of angiogenesis and metastasis, modulation of estrogen receptor signaling, suppression of inflammatory pathways, and reversal of multidrug resistance. Advances in pharmaceutical and nanotechnology-based delivery systems have further improved the bioavailability, stability, and tumor-targeting potential of these phytochemicals, thereby enhancing therapeutic efficacy while reducing adverse effects. However, despite promising preclinical and early clinical findings, challenges such as lack of standardization, quality control issues, herb–drug interactions, regulatory complexity, and limited large-scale clinical trials continue to hinder widespread clinical adoption. This review critically evaluates the global burden of breast cancer, the scientific rationale for phytotherapy, key phytochemicals and their molecular mechanisms, emerging delivery strategies, and available clinical evidence. Integrating evidence-based phytotherapy with conventional oncologic treatments may offer a safer, more effective, and accessible approach to improving breast cancer outcomes, particularly in resource-limited settings.

Keywords: Breast cancer; Herbal medicines; Phytotherapy; Plant-derived bioactive compounds; Evidence-based therapy; Nanotechnology-based drug delivery.

I. INTRODUCTION

Breast cancer is the most commonly diagnosed malignancy among women worldwide and represents a major public health burden. According to recent global cancer statistics, breast cancer accounts for approximately 25% of all female cancer cases and remains one of the leading causes of cancer-related mortality among women, with over 2.3 million new cases and more than 685,000 deaths reported globally in 2020 alone [1,2]. Although advances in early detection and therapeutic interventions have improved survival rates in high-income countries, breast cancer mortality continues to be disproportionately high in low- and middle-income regions due to limited access to screening, diagnosis, and advanced treatment modalities [1].

Breast cancer is a biologically heterogeneous disease encompassing multiple molecular subtypes, including hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive, and triple-negative breast cancer (TNBC). Each subtype exhibits distinct molecular characteristics, treatment responses, and prognostic outcomes [3]. Conventional treatment strategies—such as surgery, chemotherapy, radiotherapy, endocrine therapy, targeted therapy, and immunotherapy—have significantly enhanced disease control and survival. However, these approaches are frequently associated with substantial limitations, including systemic toxicity, high treatment costs, reduced quality of life, tumor recurrence, and the emergence of multidrug resistance (MDR) [4,5]. In particular, aggressive subtypes such as TNBC lack effective targeted therapies and are associated with poor clinical outcomes, underscoring the need for alternative and complementary therapeutic strategies [3].

In recent years, increasing attention has been directed toward complementary and alternative medicine (CAM) approaches, especially those derived from natural sources. Phytotherapy, defined as the therapeutic use of plant-derived bioactive compounds, has a long-standing history in traditional medical systems such as Ayurveda, Traditional Chinese Medicine (TCM), and indigenous healing practices worldwide. Importantly, natural products have played a pivotal role in modern drug discovery; approximately one-third of small-molecule anticancer drugs approved between 1981 and 2019 are derived directly from natural products, and nearly

two-thirds are natural product-inspired compounds [6]. This highlights the continued relevance of medicinal plants as valuable sources of anticancer agents.

Herbal medicines contain a diverse array of phytochemicals, including flavonoids, alkaloids, polyphenols, terpenoids, lignans, and isoflavones, many of which exhibit potent anticancer activities. These compounds exert their effects through multitargeted mechanisms such as induction of apoptosis, inhibition of angiogenesis and metastasis, modulation of estrogen receptor signaling, suppression of inflammatory pathways, and regulation of oxidative stress [7,8]. Unlike conventional single-target drugs, phytochemicals often act on multiple signaling pathways simultaneously, offering potential advantages in overcoming drug resistance and reducing treatment-related toxicity [9].

Despite extensive preclinical evidence supporting the anticancer potential of phytochemicals, their clinical translation has been limited by challenges such as poor aqueous solubility, low bioavailability, rapid metabolism, and variability in herbal formulations. To address these limitations, significant progress has been made in pharmaceutical and nanotechnology-based drug delivery systems, including liposomes, polymeric nanoparticles, solid lipid nanoparticles, nanogels, and microemulsions. These advanced delivery platforms enhance the stability, bioavailability, and tumor-targeting efficiency of phytochemicals, thereby improving therapeutic efficacy while minimizing systemic adverse effects [10,11].

Given the growing global burden of breast cancer and the limitations of existing therapies, there is an urgent need to explore safer, more effective, and affordable treatment options. Evidence-based phytotherapy represents a promising complementary approach that may enhance conventional treatment outcomes, reduce toxicity, and improve patient quality of life. This review aims to critically evaluate the role of herbal medicines and phytotherapy in breast cancer management by examining key phytochemicals, their molecular mechanisms of action, advances in delivery systems, available clinical evidence, and future research directions, with the goal of facilitating their rational integration into modern oncology practice.

II. GLOBAL BURDEN OF BREAST CANCER

Breast cancer represents a substantial and growing global health challenge and is currently the most frequently diagnosed cancer among women worldwide. According to the Global Cancer Observatory (GLOBOCAN), breast cancer surpassed lung cancer as the most commonly diagnosed malignancy in 2020, accounting for approximately 2.3 million new cases and more than 685,000 deaths globally [1,2]. It contributes nearly one in four cancer cases among women, highlighting its profound epidemiological and socioeconomic impact.

The global distribution of breast cancer incidence and mortality shows marked geographical disparities. High-income countries report higher incidence rates, largely due to widespread screening programs and improved diagnostic capabilities, whereas low- and middle-income countries experience disproportionately higher mortality rates [1,3]. This imbalance is primarily attributed to delayed diagnosis, limited access to specialized oncology care, and restricted availability of advanced therapeutic interventions. Consequently, breast cancer survival rates exceed 85–90% in developed nations but remain below 60% in several developing regions [3].

Breast cancer is a biologically heterogeneous disease encompassing distinct molecular subtypes, including hormone receptor-positive (estrogen receptor and/or progesterone receptor positive), human epidermal growth factor receptor 2 (HER2)-positive, and triple-negative breast cancer (TNBC). Each subtype is associated with unique molecular characteristics, treatment responses, and prognostic outcomes [4]. TNBC, which lacks estrogen, progesterone, and HER2 receptors, is particularly aggressive and associated with early recurrence, poor survival, and limited targeted treatment options [5].

Despite significant advancements in conventional therapeutic strategies—such as surgery, chemotherapy, radiotherapy, endocrine therapy, targeted therapy, and immunotherapy—breast cancer management continues to face major limitations. Chemotherapeutic regimens often lack tumor selectivity, leading to systemic toxicity, immunosuppression, cardiotoxicity, neurotoxicity, and reduced quality of life [6]. Moreover, the emergence of multidrug resistance (MDR), mediated by mechanisms such as P-glycoprotein overexpression and alterations in apoptotic signaling pathways, significantly compromises long-term treatment efficacy [7].

The economic burden of breast cancer further exacerbates its global impact. High treatment costs associated with prolonged chemotherapy, targeted biological agents, and supportive care place significant financial strain on healthcare systems and patients alike. These challenges are particularly pronounced in resource-limited settings, where affordability and accessibility remain major

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 2, February 2026 ijppr.humanjournals.com ISSN: 2349-7203

barriers to optimal care [8]. As a result, there is a growing need for alternative and complementary strategies that are cost-effective, accessible, and capable of enhancing therapeutic outcomes while minimizing toxicity.

Given the rising global incidence of breast cancer, persistent mortality disparities, and limitations of existing treatments, the exploration of novel therapeutic approaches is imperative. In this context, phytotherapy and plant-derived bioactive compounds have emerged as promising adjuncts to conventional therapy, offering potential benefits in terms of safety, affordability, and multitarget anticancer activity. Understanding the global burden of breast cancer provides a critical foundation for evaluating the role of evidence-based phytotherapy in modern oncologic practice.



Figure 1: Global incidence and mortality of breast cancer by geographical region.

The figure illustrates worldwide breast cancer incidence and mortality rates, highlighting significant regional disparities. Higher incidence rates are observed in high-income countries, while mortality remains disproportionately elevated in low- and middle-income regions due to limited access to early diagnosis and advanced treatment facilities.
Source: GLOBOCAN 2020, World Health Organization (WHO).



Figure 2: Molecular subtypes of breast cancer and associated therapeutic challenges.

Schematic representation of major breast cancer subtypes, including estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-positive, and triple-negative breast cancer (TNBC), along with their key therapeutic limitations such as hormone resistance, targeted therapy failure, aggressive behavior, and high recurrence risk.

III. RATIONALE FOR PHYTOTHERAPY IN BREAST CANCER

The continued rise in breast cancer incidence and the limitations of conventional therapeutic approaches have intensified the search for complementary and alternative strategies that are both effective and safe. Although current treatment modalities—such as surgery, chemotherapy, radiotherapy, endocrine therapy, and targeted therapy—have significantly improved patient survival, their clinical utility is often constrained by severe adverse effects, development of multidrug resistance (MDR), tumor recurrence, and high economic burden [1,2]. These challenges are particularly evident in aggressive subtypes such as triple-negative breast cancer, for which effective targeted therapies remain limited [3].

Phytotherapy, defined as the therapeutic use of plant-derived bioactive compounds, has emerged as a promising adjunct approach in breast cancer management. Medicinal plants have historically served as a rich source of anticancer agents, and natural products continue to play a central role in modern drug discovery. It is estimated that approximately one-third of small-molecule anticancer drugs approved over the past several decades are directly derived from natural products, while nearly two-thirds are either natural product-inspired or structural analogs [4]. This highlights the substantial translational potential of phytochemicals in oncology.

A major rationale for phytotherapy lies in the multitargeted nature of plant-derived compounds. Unlike conventional chemotherapeutic agents that often act on a single molecular target, phytochemicals modulate multiple signaling pathways involved in cancer initiation, progression, and metastasis. These include pathways regulating apoptosis, cell cycle progression, angiogenesis, inflammation, oxidative stress, estrogen receptor signaling, and immune modulation [5,6]. Such pleiotropic activity is particularly advantageous in breast cancer, where pathway redundancy and molecular heterogeneity contribute to therapeutic resistance.

Another important consideration is the ability of phytochemicals to enhance the efficacy of conventional therapies while reducing treatment-related toxicity. Several plant-derived compounds have demonstrated synergistic effects when combined with standard chemotherapeutic agents, leading to improved tumor response and reduced adverse effects. For example, phytochemicals such as curcumin, genistein, and resveratrol have been shown to sensitize breast cancer cells to chemotherapy and radiotherapy by modulating drug efflux transporters, inhibiting survival signaling pathways, and promoting apoptosis [7,8]. These properties suggest a valuable role for phytotherapy in overcoming MDR and improving long-term treatment outcomes.

Phytotherapy also offers potential advantages in terms of safety, affordability, and accessibility. Herbal medicines are widely used across different cultures and healthcare systems, particularly in low- and middle-income countries where access to advanced oncologic treatments may be limited. When appropriately standardized and scientifically validated, phytotherapeutic agents may provide cost-effective and culturally acceptable complementary options for breast cancer care [9]. However, it is important to emphasize that phytotherapy should not be viewed as a replacement for evidence-based conventional treatments but rather as an integrative approach that complements standard oncology practices.

Despite these promising attributes, the clinical application of phytotherapy faces several challenges, including variability in plant composition, lack of standardized formulations, potential herb–drug interactions, and limited large-scale clinical trials. Addressing these issues through rigorous scientific validation, quality control, and regulatory oversight is essential for the safe integration of phytotherapy into modern breast cancer management [10].

In summary, the rationale for phytotherapy in breast cancer is supported by its multitargeted mechanisms of action, potential to enhance conventional therapies, favorable safety profile, and global accessibility. A deeper understanding of phytochemical mechanisms, combined with advances in pharmaceutical formulation and clinical research, may enable the rational incorporation of evidence-based phytotherapy into integrative breast cancer treatment strategies.

IV. MECHANISMS OF ACTION OF PHYTOCHEMICALS IN BREAST CANCER

Phytochemicals exert anticancer effects through a broad spectrum of molecular and cellular mechanisms, distinguishing them from conventional single-target chemotherapeutic agents. The ability of plant-derived bioactive compounds to simultaneously modulate

multiple oncogenic pathways is particularly advantageous in breast cancer, a disease characterized by molecular heterogeneity, pathway redundancy, and therapeutic resistance [1,2]. The principal mechanisms by which phytochemicals inhibit breast cancer initiation, progression, and metastasis are summarized below.

4.1 Induction of Apoptosis and Cell Cycle Arrest

One of the most extensively documented anticancer mechanisms of phytochemicals is their ability to induce programmed cell death (apoptosis) and disrupt uncontrolled cell proliferation. Compounds such as curcumin, genistein, resveratrol, and berberine activate both intrinsic (mitochondrial) and extrinsic apoptotic pathways in breast cancer cells. These effects are mediated through modulation of key apoptotic regulators, including upregulation of pro-apoptotic proteins (Bax, Bad, caspases) and downregulation of anti-apoptotic proteins (Bcl-2, Bcl-xL) [3,4].

In addition to apoptosis, phytochemicals induce cell cycle arrest at critical checkpoints, particularly the G1/S and G2/M phases. This is achieved through regulation of cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors such as p21, p27, and p53. Arresting the cell cycle limits tumor cell proliferation and sensitizes cancer cells to chemotherapeutic agents [5].

4.2 Inhibition of Angiogenesis and Metastasis

Tumor growth and metastasis depend on angiogenesis and the ability of cancer cells to invade surrounding tissues. Several phytochemicals exhibit potent anti-angiogenic and anti-metastatic properties. Polyphenols and flavonoids suppress vascular endothelial growth factor (VEGF) signaling, inhibit endothelial cell migration, and reduce neovascularization within tumors [6].

Phytochemicals also interfere with epithelial–mesenchymal transition (EMT), a critical process involved in cancer metastasis. By downregulating EMT-associated transcription factors such as Snail, Slug, and Twist, and inhibiting matrix metalloproteinases (MMP-2 and MMP-9), these compounds significantly reduce breast cancer cell invasion and migration [7].

4.3 Modulation of Hormonal and Growth Factor Signaling

Hormone receptor signaling plays a pivotal role in the pathogenesis of many breast cancers. Phytoestrogens such as genistein exhibit selective estrogen receptor modulatory activity, enabling them to act as estrogen agonists or antagonists depending on the hormonal environment. This dual activity allows phytochemicals to inhibit estrogen-driven tumor growth while minimizing adverse hormonal effects [8].

Additionally, phytochemicals modulate growth factor-mediated signaling pathways, including PI3K/Akt/mTOR, MAPK/ERK, and HER2-related pathways. By inhibiting these oncogenic cascades, phytochemicals suppress cell survival, proliferation, and resistance to therapy [9].

4.4 Anti-inflammatory and Antioxidant Effects

Chronic inflammation and oxidative stress contribute significantly to breast cancer development and progression. Many plant-derived compounds possess strong anti-inflammatory and antioxidant properties. Phytochemicals inhibit nuclear factor kappa B (NF-κB) activation and reduce the production of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukins [10].

By scavenging reactive oxygen species (ROS) and enhancing endogenous antioxidant defenses, phytochemicals protect normal cells from oxidative damage while selectively inducing oxidative stress-mediated apoptosis in cancer cells. This dual action contributes to their favorable safety profile [11].

4.5 Targeting Cancer Stem Cells and Tumor Microenvironment

Cancer stem cells (CSCs) are implicated in tumor recurrence, metastasis, and resistance to therapy. Emerging evidence suggests that phytochemicals such as curcumin and resveratrol can target breast cancer stem cells by inhibiting self-renewal pathways, including Wnt/β-catenin, Notch, and Hedgehog signaling [12].

Furthermore, phytochemicals modulate the tumor microenvironment by altering immune cell infiltration, reducing immunosuppressive signaling, and enhancing antitumor immune responses. These effects contribute to sustained tumor control and improved therapeutic outcomes [13].

4.6 Reversal of Multidrug Resistance

Multidrug resistance (MDR) remains a major obstacle in breast cancer treatment. Several phytochemicals have demonstrated the ability to reverse MDR by inhibiting drug efflux transporters such as P-glycoprotein and modulating survival signaling pathways. By increasing intracellular drug accumulation and restoring chemosensitivity, phytochemicals enhance the efficacy of conventional chemotherapeutic agents [14].

Summary of Mechanistic Advantages

Collectively, phytochemicals target multiple hallmarks of breast cancer, including sustained proliferation, evasion of apoptosis, angiogenesis, metastasis, inflammation, immune evasion, and drug resistance. This multitargeted mode of action underpins their potential as effective adjuncts in integrative breast cancer therapy and provides a strong scientific basis for further clinical development.



Figure 3: Multi- Targeted Mechanism of Phytochemicals in Breast Cancer

The diagram illustrates the principal anticancer mechanisms of phytochemicals, including induction of apoptosis, cell cycle arrest, inhibition of angiogenesis, suppression of epithelial–mesenchymal transition (EMT), and reversal of multidrug resistance (MDR), collectively contributing to inhibition of breast cancer progression.

V. KEY PHYTOCHEMICALS IN BREAST CANCER

5.1 Curcumin (Curcuma longa)

Curcumin is a naturally occurring polyphenolic compound derived from the rhizomes of Curcuma longa (turmeric), a medicinal plant widely used in traditional systems such as Ayurveda and Traditional Chinese Medicine. Chemically, curcumin is known as diferuloylmethane and belongs to the curcuminoid class of compounds. Owing to its broad pharmacological profile, curcumin has attracted significant attention as a promising anticancer agent, particularly in breast cancer research [1,2].

5.1.1 Anticancer Mechanisms of Curcumin in Breast Cancer

Curcumin exhibits potent anticancer activity through modulation of multiple molecular and cellular pathways involved in breast cancer progression. One of its most important mechanisms is the induction of apoptosis via both intrinsic and extrinsic pathways. Curcumin upregulates pro-apoptotic proteins such as Bax, caspase-3, and caspase-9, while downregulating anti-apoptotic proteins including Bcl-2 and Bcl-xL, leading to mitochondrial membrane depolarization and programmed cell death [3,4].

In addition to apoptosis, curcumin induces cell cycle arrest at the G1/S and G2/M checkpoints by modulating cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors such as p21 and p27. These effects result in suppressed proliferation of breast cancer cells across multiple cell lines, including MCF-7, MDA-MB-231, and T47D [5].

Curcumin also exerts strong anti-metastatic and anti-angiogenic effects. It inhibits epithelial–mesenchymal transition (EMT) by downregulating transcription factors such as Snail and Twist and suppresses matrix metalloproteinases (MMP-2 and MMP-9), thereby reducing invasion and migration of breast cancer cells [6]. Furthermore, curcumin inhibits vascular endothelial growth factor (VEGF) signaling, limiting tumor angiogenesis and metastatic spread [7].

5.1.2 Modulation of Oncogenic Signaling Pathways

A key advantage of curcumin is its ability to modulate multiple oncogenic signaling pathways simultaneously. It suppresses activation of nuclear factor kappa B (NF-κB), phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), and mammalian target of rapamycin (mTOR) pathways, all of which play critical roles in breast cancer cell survival, proliferation, and resistance to therapy [8,9]. Curcumin has also been shown to interfere with estrogen receptor signaling, making it particularly relevant for hormone-dependent breast cancers [10].

5.1.3 Reversal of Multidrug Resistance and Synergistic Effects

Multidrug resistance (MDR) is a major obstacle in breast cancer treatment. Curcumin has demonstrated the ability to reverse MDR by inhibiting drug efflux transporters such as P-glycoprotein and modulating survival signaling pathways. By increasing intracellular accumulation of chemotherapeutic agents, curcumin enhances the sensitivity of resistant breast cancer cells to drugs such as doxorubicin, paclitaxel, and tamoxifen [11,12].

Several studies have reported synergistic anticancer effects when curcumin is combined with conventional chemotherapy or radiotherapy. These combinations result in improved tumor inhibition while reducing chemotherapy-associated toxicity, highlighting curcumin's potential as an effective adjuvant therapy [13].

5.1.4 Bioavailability Challenges and Advanced Delivery Systems

Despite its potent anticancer properties, the clinical application of curcumin is limited by poor aqueous solubility, low bioavailability, rapid metabolism, and systemic elimination. To overcome these limitations, advanced drug delivery systems such as liposomes, polymeric nanoparticles, solid lipid nanoparticles, nanogels, and microemulsions have been developed. These formulations significantly enhance curcumin's stability, absorption, and tumor-targeting efficiency, leading to improved therapeutic outcomes in breast cancer models [14,15].

5.1.5 Clinical Evidence and Safety Profile

Preclinical studies consistently demonstrate curcumin's efficacy against breast cancer in vitro and in vivo. Early-phase clinical trials have reported that curcumin, either alone or in combination with chemotherapeutic agents, is well tolerated and associated with minimal toxicity. Clinical evidence also suggests that curcumin supplementation may reduce treatment-related side effects and improve quality of life in breast cancer patients [16].

Summary

Collectively, curcumin represents one of the most extensively studied and promising phytochemicals for breast cancer management. Its multitargeted mechanisms of action, ability to reverse drug resistance, favorable safety profile, and potential for synergistic use with conventional therapies provide strong justification for its inclusion in evidence-based phytotherapy approaches. Further large-scale clinical trials and standardized formulations are required to fully establish its therapeutic role in clinical oncology.

5.2 Genistein (Glycine max)

Genistein (4′,5,7-trihydroxyisoflavone) is a naturally occurring isoflavone predominantly found in soybeans (Glycine max) and other leguminous plants. As a phytoestrogen, genistein structurally resembles 17β-estradiol and exhibits selective estrogen receptor (ER) modulatory activity. Extensive experimental and epidemiological studies have demonstrated its potential role in the prevention and treatment of breast cancer, particularly hormone-dependent subtypes [1,2].

5.2.1 Anticancer Mechanisms of Genistein

Genistein exerts significant antiproliferative and pro-apoptotic effects in breast cancer cells through multiple molecular pathways. It induces apoptosis by modulating the balance between pro-apoptotic and anti-apoptotic proteins, including upregulation of Bax and caspase-3 and downregulation of Bcl-2 and Bcl-xL. These effects activate both mitochondrial and endoplasmic reticulum stress–mediated apoptotic pathways [3,4].

Genistein also induces cell cycle arrest, predominantly at the G2/M phase, by inhibiting cyclin-dependent kinases and regulating cell cycle checkpoint proteins. Increased expression of p21^WAF1/CIP1^ and suppression of Cdc25C phosphatase activity contribute to growth inhibition in breast cancer cell lines such as MCF-7 and MDA-MB-231 [5].

5.2.2 Estrogen Receptor Modulation and Hormonal Effects

One of the distinguishing features of genistein is its selective estrogen receptor modulatory activity. Genistein exhibits a higher binding affinity for estrogen receptor beta (ERβ) than estrogen receptor alpha (ERα), allowing it to function as either an estrogen agonist or antagonist depending on endogenous estrogen levels and tissue context [6]. This dual activity enables genistein to inhibit estrogen-driven tumor growth in hormone-dependent breast cancers while exerting minimal proliferative effects on normal breast tissue.

Additionally, genistein interferes with estrogen-mediated transcriptional activity and suppresses aromatase expression, thereby reducing local estrogen synthesis within breast tumors [7].

5.2.3 Epigenetic and Signaling Pathway Regulation

Emerging evidence indicates that genistein exerts epigenetic effects that contribute to its anticancer activity. Genistein inhibits DNA methyltransferases (DNMTs), leading to hypomethylation and reactivation of tumor suppressor genes such as PTEN, ATM, and BRCA1. These epigenetic modifications restore normal cell cycle regulation and apoptotic responses in breast cancer cells [8].

Genistein also modulates key oncogenic signaling pathways, including PI3K/Akt, NF-κB, and MAPK pathways, resulting in reduced cell survival, proliferation, and metastatic potential. In triple-negative breast cancer models, genistein has demonstrated the ability to suppress invasion and migration by inhibiting Akt-mediated signaling cascades [9].

5.2.4 Anti-metastatic and Anti-angiogenic Effects

Genistein exhibits strong anti-metastatic properties by inhibiting epithelial–mesenchymal transition (EMT) and reducing matrix metalloproteinase activity. Suppression of MMP-2 and MMP-9 expression limits extracellular matrix degradation and tumor cell invasion [10]. Furthermore, genistein inhibits angiogenesis by downregulating vascular endothelial growth factor (VEGF) signaling, thereby restricting tumor vascularization and metastatic spread [11].

5.2.5 Synergistic Effects and Clinical Relevance

Genistein has demonstrated synergistic anticancer effects when combined with conventional chemotherapeutic agents and hormonal therapies. Studies have shown that genistein enhances the efficacy of tamoxifen and restores hormone sensitivity in estrogen receptor–negative breast cancer cells by reactivating ER expression through epigenetic mechanisms [12]. These findings suggest that genistein may expand therapeutic options for hormone-resistant and triple-negative breast cancers.

Epidemiological studies further support the clinical relevance of genistein, as populations with high dietary soy intake exhibit lower breast cancer incidence and recurrence rates. Importantly, genistein is generally well tolerated, with minimal toxicity reported at dietary and supplemental doses [13].

Summary

Genistein is a well-characterized phytoestrogen with significant anticancer potential in breast cancer management. Its ability to modulate estrogen receptor signaling, induce apoptosis, regulate epigenetic mechanisms, inhibit metastasis, and enhance responsiveness to conventional therapies highlights its value as a complementary phytotherapeutic agent. Further clinical trials are warranted to optimize dosing strategies and establish its role in integrative breast cancer treatment protocols.

5.3 Resveratrol (Vitis vinifera)

Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a naturally occurring polyphenolic stilbene predominantly found in the skins of grapes (Vitis vinifera), red wine, peanuts, and various berries. Initially recognized for its cardioprotective properties, resveratrol has gained considerable attention for its anticancer potential, particularly in hormone-dependent and aggressive subtypes of breast cancer [1,2].

5.3.1 Anticancer Mechanisms of Resveratrol

Resveratrol exhibits potent antiproliferative and pro-apoptotic effects in breast cancer cells through both intrinsic and extrinsic apoptotic pathways. It activates mitochondrial-mediated apoptosis by increasing the expression of pro-apoptotic proteins such as Bax and caspase-9 while suppressing anti-apoptotic proteins including Bcl-2, Bcl-xL, and XIAP. These effects lead to cytochrome c release, caspase cascade activation, and programmed cell death in breast cancer cell lines such as MCF-7 and MDA-MB-231 [3,4].

In addition to apoptosis, resveratrol induces cell cycle arrest, predominantly at the G1/S phase, by modulating cyclins, cyclin-dependent kinases, and tumor suppressor proteins such as p53 and p21. This inhibition of cell cycle progression effectively limits tumor cell proliferation [5].

5.3.2 Modulation of Oncogenic Signaling Pathways

Resveratrol targets multiple oncogenic signaling pathways implicated in breast cancer progression. It suppresses activation of the PI3K/Akt/mTOR pathway, thereby inhibiting cell survival and growth. Resveratrol also modulates mitogen-activated protein kinase (MAPK) signaling and downregulates nuclear factor kappa B (NF-κB), resulting in reduced inflammation, proliferation, and resistance to apoptosis [6,7].

Furthermore, resveratrol interferes with estrogen receptor signaling by acting as a selective estrogen receptor modulator, enabling it to exert anti-estrogenic effects in hormone-dependent breast cancers while maintaining minimal estrogenic activity in normal tissues [8].

5.3.3 Anti-metastatic, Anti-angiogenic, and Metabolic Effects

Resveratrol demonstrates strong anti-metastatic activity by inhibiting epithelial–mesenchymal transition (EMT), reducing cancer cell migration and invasion. It suppresses the expression of matrix metalloproteinases (MMP-2 and MMP-9) and downregulates EMT-associated transcription factors such as Snail and ZEB1 [9].

In addition, resveratrol inhibits angiogenesis by reducing vascular endothelial growth factor (VEGF) expression and impairing endothelial cell proliferation. It also disrupts cancer cell metabolism by modulating glycolytic enzymes and targeting metabolic regulators such as c-Myc, thereby limiting energy production required for tumor growth [10].

5.3.4 Regulation of MicroRNAs and Cancer Stem Cells

Recent studies indicate that resveratrol exerts anticancer effects through regulation of tumor-suppressive microRNAs. It modulates the expression of microRNAs involved in apoptosis, cell cycle regulation, and metastasis, including miR-125b, miR-200c, and miR-34a. These microRNAs contribute to reduced stemness, enhanced chemosensitivity, and inhibition of tumor recurrence [11].

Resveratrol has also been shown to target breast cancer stem cells by inhibiting self-renewal signaling pathways such as Wnt/β-catenin and Notch, thereby reducing tumor relapse and resistance to therapy [12].

5.3.5 Synergistic Effects, Bioavailability, and Clinical Considerations

Resveratrol exhibits synergistic anticancer effects when combined with chemotherapeutic agents and radiotherapy. Co-administration with drugs such as doxorubicin, paclitaxel, and tamoxifen enhances apoptotic responses and reduces treatment resistance in breast cancer models [13].

Despite its promising pharmacological properties, resveratrol's clinical application is limited by poor aqueous solubility, rapid metabolism, and low systemic bioavailability. Advanced delivery systems, including nanoparticles, liposomes, and solid lipid carriers, have been developed to overcome these limitations and improve therapeutic efficacy [14].

Early-phase clinical studies suggest that resveratrol is generally safe and well tolerated, although further large-scale trials are required to establish optimal dosing, long-term safety, and clinical efficacy in breast cancer patients [15].

Summary

Resveratrol is a multifunctional phytochemical with significant anticancer activity against breast cancer. Its ability to induce apoptosis, inhibit metastasis and angiogenesis, regulate oncogenic signaling and microRNAs, and enhance the efficacy of conventional therapies underscores its potential as a valuable component of evidence-based phytotherapy. Continued research focusing on improved delivery systems and rigorous clinical validation is essential to translate resveratrol's promising preclinical findings into clinical practice.

5.4 Berberine (Berberis spp., Coptis chinensis)

Berberine is a naturally occurring isoquinoline alkaloid isolated from several medicinal plants, including Berberis vulgaris, Hydrastis canadensis, and Coptis chinensis. Traditionally used in Chinese and Ayurvedic medicine for its antimicrobial and anti-inflammatory properties, berberine has emerged as a potent anticancer agent with broad-spectrum activity against multiple malignancies, including breast cancer [1,2].

5.4.1 Antiproliferative and Cell Cycle Regulatory Effects

Berberine exhibits strong antiproliferative effects in breast cancer cells by inducing cell cycle arrest at various checkpoints, particularly the G0/G1 and G2/M phases. These effects are mediated through downregulation of cyclins (cyclin D1 and cyclin B1) and cyclin-dependent kinases, along with upregulation of CDK inhibitors such as p21 and p27. Studies in breast cancer cell lines, including MCF-7 and MDA-MB-231, demonstrate that berberine effectively suppresses tumor cell proliferation in a dose-dependent manner [3,4].

5.4.2 Induction of Apoptosis via Mitochondrial Pathways

Berberine induces apoptosis primarily through the intrinsic mitochondrial pathway. It promotes mitochondrial membrane depolarization, increases the Bax/Bcl-2 ratio, and activates caspase-9 and caspase-3, ultimately leading to programmed cell death. Additionally, berberine enhances reactive oxygen species (ROS) generation in cancer cells, triggering oxidative stress–mediated apoptosis while sparing normal cells [5,6].

5.4.3 Modulation of Oncogenic Signaling Pathways

Berberine targets several key oncogenic signaling pathways involved in breast cancer progression. It inhibits the PI3K/Akt/mTOR pathway, leading to reduced cell survival and proliferation. Berberine also suppresses nuclear factor kappa B (NF-κB) activation, resulting in decreased expression of anti-apoptotic and inflammatory genes [7].

Furthermore, berberine activates AMP-activated protein kinase (AMPK), a central regulator of cellular energy homeostasis. AMPK activation contributes to metabolic reprogramming of cancer cells, inhibition of lipid synthesis, and suppression of tumor growth [8].

5.4.4 Anti-metastatic, Anti-inflammatory, and MDR-Reversal Effects

Berberine exhibits pronounced anti-metastatic properties by inhibiting epithelial–mesenchymal transition (EMT) and suppressing matrix metalloproteinases (MMP-2 and MMP-9), thereby reducing invasion and migration of breast cancer cells. These effects are mediated through inhibition of Akt/NF-κB signaling and downregulation of EMT-associated transcription factors [9].

Chronic inflammation plays a crucial role in breast cancer progression, particularly in aggressive subtypes. Berberine exerts strong anti-inflammatory effects by reducing pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukins, further contributing to its anticancer activity [10].

Importantly, berberine has demonstrated the ability to reverse multidrug resistance (MDR) in breast cancer cells. By inhibiting P-glycoprotein activity and modulating drug efflux mechanisms, berberine increases intracellular accumulation of chemotherapeutic agents and restores chemosensitivity in resistant cancer cells [11].

5.4.5 Bioavailability, Safety, and Clinical Potential

Compared with many other phytochemicals, berberine exhibits relatively favorable oral bioavailability; however, its absorption remains limited by first-pass metabolism. To address this issue, novel formulations such as nanoparticles, lipid-based carriers, and phospholipid complexes have been developed to enhance systemic exposure and therapeutic efficacy [12].

Preclinical studies consistently demonstrate that berberine is well tolerated, with minimal toxicity to normal tissues. Early clinical observations suggest a favorable safety profile, although comprehensive clinical trials evaluating its efficacy and optimal dosing in breast cancer patients remain limited [13].

Summary

Berberine is a multifunctional phytochemical with significant anticancer potential in breast cancer management. Its ability to inhibit proliferation, induce apoptosis, suppress metastasis and inflammation, modulate metabolic pathways, and reverse multidrug resistance underscores its value as a promising adjunct in evidence-based phytotherapy. Continued research focusing on advanced delivery systems and robust clinical validation is essential to establish berberine's role in integrative breast cancer treatment strategies.

VI. NANOTECHNOLOGY & ADVANCED DELIVERY SYSTEMS

Despite the strong anticancer potential demonstrated by phytochemicals in breast cancer, their clinical translation is often limited by unfavorable pharmacokinetic properties, including poor aqueous solubility, low oral bioavailability, rapid metabolism, and nonspecific systemic distribution. These limitations result in subtherapeutic drug concentrations at tumor sites and reduced clinical efficacy [1,2]. To overcome these challenges, nanotechnology-based drug delivery systems have emerged as a promising strategy to enhance the therapeutic performance of plant-derived bioactive compounds.

Nanotechnology offers unique advantages in cancer therapy by enabling controlled drug release, improved stability, enhanced cellular uptake, and selective tumor targeting. Nanocarriers exploit the enhanced permeability and retention (EPR) effect characteristic of tumor vasculature, allowing preferential accumulation of therapeutic agents within tumor tissues while minimizing systemic toxicity [3]. This approach is particularly relevant for breast cancer, where targeted delivery can significantly improve therapeutic outcomes and reduce adverse effects.

6.1 Liposomes and Phospholipid-Based Systems

Liposomes are spherical vesicles composed of phospholipid bilayers capable of encapsulating both hydrophilic and lipophilic compounds. Liposomal formulations of phytochemicals such as curcumin and resveratrol have demonstrated improved solubility, prolonged circulation time, and enhanced tumor accumulation in breast cancer models [4]. By protecting phytochemicals from rapid degradation and metabolism, liposomes significantly improve bioavailability and therapeutic efficacy.

Furthermore, surface modification of liposomes with targeting ligands—such as antibodies or peptides—enables selective delivery to breast cancer cells expressing specific receptors, including HER2 and estrogen receptors, thereby enhancing specificity and reducing off-target effects [5].

6.2 Polymeric Nanoparticles and Micelles

Polymeric nanoparticles and micelles, typically composed of biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG), have been extensively explored for phytochemical delivery. These systems provide controlled and sustained release of encapsulated compounds, protecting them from premature degradation [6].

Curcumin-, genistein-, and berberine-loaded polymeric nanoparticles have shown enhanced cellular uptake, increased apoptosis induction, and improved antitumor efficacy in breast cancer cell lines and animal models. Additionally, polymeric micelles are particularly effective in solubilizing hydrophobic phytochemicals, thereby improving their oral and intravenous bioavailability [7].

6.3 Solid Lipid Nanoparticles and Nanostructured Lipid Carriers

Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) represent advanced lipid-based delivery systems that combine the advantages of liposomes and polymeric nanoparticles. These systems offer improved physical stability, high drug loading capacity, and controlled release profiles [8].

Phytochemicals such as curcumin and resveratrol formulated within SLNs and NLCs have demonstrated enhanced anticancer activity, reduced systemic toxicity, and improved pharmacokinetic profiles in breast cancer models. These carriers also facilitate oral delivery, making them attractive for long-term therapeutic and preventive applications [9].

6.4 Nanogels, Microemulsions, and Hybrid Systems

Nanogels and microemulsions are emerging delivery platforms that offer high drug-loading efficiency and excellent stability. Microemulsions, which are thermodynamically stable colloidal systems composed of oil, water, and surfactants, enhance the solubilization and absorption of lipophilic phytochemicals without requiring high energy input [10].

Hybrid nanocarrier systems that combine phytochemicals with imaging agents or phototherapeutic components have also gained attention. These "theranostic" platforms enable simultaneous diagnosis, targeted therapy, and treatment monitoring, thereby advancing personalized breast cancer management [11].

6.5 Clinical Relevance and Translational Potential

Nanotechnology-based delivery systems significantly enhance the clinical applicability of phytochemicals by improving therapeutic indices and reducing dose-limiting toxicity. By enabling co-delivery of phytochemicals with conventional chemotherapeutic agents, nanocarriers facilitate synergistic interactions and overcome multidrug resistance mechanisms [12].

Although most nanophytotherapeutic formulations are currently in preclinical or early clinical development, accumulating evidence supports their potential role in integrative breast cancer therapy. Continued optimization of formulation design, large-scale manufacturing, regulatory standardization, and clinical validation will be essential for successful translation into routine oncology practice [13].

Summary

Nanotechnology and advanced delivery systems represent a critical bridge between promising phytochemical research and clinical application in breast cancer. By overcoming bioavailability limitations and enabling targeted, controlled delivery, these technologies substantially enhance the therapeutic potential of phytochemicals such as curcumin, genistein, resveratrol, and berberine. Integration of nanotechnology with evidence-based phytotherapy holds significant promise for the development of safer, more effective, and personalized breast cancer treatment strategies.



Figure 4:Nanotechnology-based Delivery System

Overview of advanced nanocarrier platforms used to enhance the bioavailability and therapeutic efficacy of phytochemicals, including liposomes, polymeric nanoparticles, solid lipid nanoparticles (SLNs), nanogels, and theranostic systems for targeted and controlled drug delivery.

VIII. LIMITATIONS & CHALLENGES

Despite the growing body of experimental and emerging clinical evidence supporting the anticancer potential of phytochemicals in breast cancer, several scientific, clinical, and regulatory challenges continue to limit their widespread adoption in routine oncology practice. Addressing these limitations is essential to ensure the safe, effective, and evidence-based integration of phytotherapy into breast cancer management.

8.1 Lack of Standardization and Quality Control

One of the most significant challenges in phytotherapy is the lack of standardization of herbal formulations. The concentration and composition of bioactive phytochemicals can vary substantially depending on plant species, geographic origin, cultivation conditions, harvesting time, extraction methods, and storage practices. Such variability can lead to inconsistent therapeutic outcomes and complicates reproducibility across studies. Unlike synthetic drugs, many herbal products lack rigorous quality control measures, which may result in batch-to-batch variability and contamination with heavy metals, pesticides, or adulterants [1].

8.2 Poor Bioavailability and Pharmacokinetic Limitations

Many phytochemicals, including curcumin and resveratrol, suffer from poor aqueous solubility, rapid metabolism, and limited systemic bioavailability. These pharmacokinetic constraints significantly reduce their therapeutic concentrations at tumor sites when administered in conventional formulations. Although nanotechnology-based delivery systems have shown promise in overcoming these limitations, their translation into clinical use remains limited due to scalability, cost, and regulatory hurdles [2,3].

8.3 Limited High-Quality Clinical Evidence

While preclinical studies provide strong mechanistic support for the anticancer activity of phytochemicals, robust clinical evidence remains limited. Most available clinical studies are small-scale, short-duration, or observational in nature. The lack of large, multicenter, randomized controlled trials with standardized formulations, well-defined endpoints, and long-term follow-up limits the ability to draw definitive conclusions regarding efficacy and survival benefits in breast cancer patients [4].

8.4 Herb–Drug Interactions and Safety Concerns

The concurrent use of herbal medicines with conventional anticancer therapies raises concerns regarding potential herb–drug interactions. Certain phytochemicals may influence drug-metabolizing enzymes and efflux transporters, potentially altering the pharmacokinetics and effectiveness of chemotherapeutic agents. Inappropriate or unsupervised use of herbal products may therefore compromise treatment efficacy or increase toxicity. This underscores the importance of clinical supervision, patient education, and open communication between patients and healthcare providers [5].

8.5 Regulatory and Clinical Integration Barriers

Regulatory approval pathways for herbal medicines and phytochemicals differ significantly across regions and are often less clearly defined than those for conventional pharmaceuticals. The absence of harmonized regulatory frameworks, standardized dosing guidelines, and clear clinical indications poses a major barrier to clinical integration. Additionally, limited awareness and skepticism among healthcare professionals regarding phytotherapy further hinder its incorporation into evidence-based oncology practice [6].

8.6 Patient Awareness and Misconceptions

Although patient interest in herbal and natural therapies is high, misconceptions regarding the safety and efficacy of “natural” products persist. Self-medication without medical guidance is common and may result in inappropriate use, delayed conventional treatment, or adverse interactions. Improved patient education and inclusion of phytotherapy discussions within clinical consultations are essential to ensure safe and informed decision-making [7].

Summary

While phytotherapy offers promising complementary benefits in breast cancer management, its clinical application is constrained by challenges related to standardization, bioavailability, limited clinical evidence, herb–drug interactions, regulatory complexity, and patient education. Overcoming these barriers through rigorous scientific validation, standardized formulations, advanced delivery technologies, and well-designed clinical trials is critical for the safe and effective integration of evidence-based phytotherapy into modern breast cancer care.

IX. FUTURE PERSPECTIVES

The growing scientific interest in phytotherapy reflects an important shift toward integrative, mechanism-driven, and patient-centered approaches in breast cancer management. While current evidence supports the complementary role of phytochemicals, future progress depends on addressing key scientific, technological, and clinical gaps through coordinated research and innovation.

9.1 Advancing High-Quality Clinical Research

The most critical future priority is the execution of large-scale, multicenter, randomized controlled clinical trials to establish the safety, efficacy, and survival benefits of phytochemicals in breast cancer patients. Such trials should employ standardized, well-characterized phytochemical formulations with clearly defined dosing regimens and pharmacokinetic profiling. Stratification of patients based on molecular subtype, disease stage, and treatment history will be essential to identify populations most likely to benefit from phytotherapy [1].

9.2 Precision Medicine and Biomarker-Guided Phytotherapy

Advances in molecular oncology and precision medicine provide new opportunities to personalize phytotherapy. Future studies should focus on identifying predictive biomarkers that correlate with responsiveness to specific phytochemicals, such as signaling pathway activation profiles, epigenetic markers, and metabolic signatures. Integrating phytochemicals into biomarker-driven treatment strategies may improve therapeutic selectivity, enhance efficacy, and minimize unnecessary exposure [2].

9.3 Innovations in Drug Delivery and Formulation

Continued development of advanced drug delivery systems will play a pivotal role in translating phytochemicals into clinical practice. Next-generation nanocarriers—including stimuli-responsive nanoparticles, targeted delivery systems, and theranostic platforms—have the potential to further enhance bioavailability, tumor specificity, and controlled release of phytochemicals. Combining phytochemicals with imaging agents and conventional drugs within multifunctional nanocarriers may enable real-time treatment monitoring and improved therapeutic outcomes [3,4].

9.4 Integrative Oncology and Combination Therapies

Future breast cancer treatment paradigms are likely to emphasize rational combination therapies that integrate phytochemicals with conventional treatments such as chemotherapy, endocrine therapy, targeted therapy, and immunotherapy. Understanding synergistic interactions at the molecular level will allow optimization of combination regimens that maximize tumor control while minimizing toxicity. Such integrative approaches may be particularly valuable in managing drug-resistant and recurrent breast cancers [5].

9.5 Regulatory Harmonization and Clinical Integration

To facilitate clinical adoption, regulatory frameworks governing phytochemicals and herbal medicines must evolve toward greater harmonization and scientific rigor. Establishing clear guidelines for quality control, manufacturing standards, safety assessment, and clinical evaluation will be essential. In parallel, improved education and training of healthcare professionals in evidence-based phytotherapy will support informed clinical decision-making and safe patient counseling [6].

9.6 Global Health and Accessibility Considerations

Phytotherapy holds particular promise for improving breast cancer care in low- and middle-income countries, where access to advanced oncology treatments may be limited. Developing affordable, standardized phytotherapeutic interventions could help reduce global disparities in cancer care. However, ensuring ethical research practices, equitable access, and patient safety must remain central to future efforts [7].

Summary

Future advances in evidence-based phytotherapy will depend on the convergence of rigorous clinical research, precision medicine, innovative drug delivery technologies, and integrative oncology frameworks. By addressing current limitations and leveraging emerging scientific tools, phytochemicals such as curcumin, genistein, resveratrol, and berberine may become valuable components of personalized and globally accessible breast cancer treatment strategies.

X. CONCLUSION

Breast cancer continues to represent a major global health challenge, characterized by biological heterogeneity, therapeutic resistance, systemic toxicity, and significant economic burden. Although conventional treatment modalities have substantially improved patient survival, their limitations underscore the need for complementary strategies that enhance therapeutic efficacy while minimizing adverse effects. In this context, evidence-based phytotherapy has emerged as a promising adjunct approach in breast cancer management.

A growing body of experimental and clinical evidence demonstrates that plant-derived bioactive compounds such as curcumin, genistein, resveratrol, and berberine exert significant anticancer effects through multitargeted mechanisms. These phytochemicals modulate key oncogenic pathways involved in apoptosis, cell cycle regulation, angiogenesis, metastasis, inflammation, and multidrug resistance. Their ability to act on multiple molecular targets simultaneously offers distinct advantages over conventional single-target therapies, particularly in overcoming resistance and addressing tumor heterogeneity.

Advances in pharmaceutical and nanotechnology-based delivery systems have further strengthened the translational potential of phytochemicals by improving bioavailability, stability, tumor targeting, and controlled release. Such innovations address longstanding pharmacokinetic limitations and enable the rational integration of phytochemicals into modern oncology frameworks. Emerging clinical evidence, particularly for curcumin, supports the safety and potential therapeutic value of phytochemicals as complementary agents that may enhance conventional treatment outcomes and improve patient quality of life.

Despite these encouraging developments, several challenges remain, including the need for standardized formulations, rigorous quality control, well-designed large-scale clinical trials, and clear regulatory pathways. Addressing these barriers through coordinated scientific, clinical, and regulatory efforts is essential to enable the safe and effective incorporation of phytotherapy into evidence-based breast cancer care.

In conclusion, herbal medicines and evidence-based phytotherapy hold substantial promise as complementary components of integrative breast cancer treatment strategies. Continued advancements in mechanistic research, precision medicine, advanced delivery technologies, and clinical validation may facilitate the development of safer, more effective, and accessible therapeutic options. By bridging traditional herbal knowledge with contemporary oncologic science, phytotherapy has the potential to contribute meaningfully to personalized and globally inclusive breast cancer management.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. **CA Cancer J Clin.** 2021;71(3):209–49. doi:10.3322/caac.21660.
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. **CA Cancer J Clin.** 2021;71(1):7–33. doi:10.3322/caac.21654.
3. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. **Nature.** 2000;406(6797):747–52. doi:10.1038/35021093.
4. Wang J, Seebacher N, Shi H, Kan Q, Duan Z. Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. **Oncotarget.** 2017;8(48):84559–71. doi:10.18632/oncotarget.19187.
5. Han H, Qian C, Zong G, Liu H, Wang F, Tao R, et al. Systemic pharmacological verification of *Salvia miltiorrhiza*–Ginseng herb pair in inhibiting spontaneous breast cancer metastasis. **Drug Des Devel Ther.** 2022;16:113–28. doi:10.2147/DDDT.S346201.
6. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 1981 to 2019. **J Nat Prod.** 2020;83(3):770–803. doi:10.1021/acs.jnatprod.9b01285.
7. Bertoncini-Silva C, Vlad A, Ricciarelli R, Fassini PG, Suen VMM, Zingg JM. Enhancing the bioavailability and bioactivity of curcumin for disease prevention and treatment. **Antioxidants.** 2024;13(3):331. doi:10.3390/antiox13030331.
8. Karnwal A, Jassim AY, Mohammed AA, Sharma V, Al-Tawaha ARM, Sivanesan I. Nanotechnology for healthcare: Plant-derived nanoparticles in disease treatment and regenerative medicine. **Pharmaceuticals.** 2024;17(12):1711. doi:10.3390/ph17121711.
9. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. **Int J Biochem Cell Biol.** 2009;41(1):40–59. doi:10.1016/j.biocel.2008.06.010.
10. Patankar SB, Mujumdar AM, Bernard F, Supriya P. Safety and efficacy of an herbal formulation: A randomized, double-blind, placebo-controlled study. **J Ayurveda Integr Med.** 2020;11(1):62–70. doi:10.1016/j.jaim.2018.12.002.
11. Russo M, Russo GL. Daglia M, Kasi PD, Ravi S, Nabavi SF, et al. Understanding genistein in cancer: The “good” and the “bad” effects. **Mol Nutr Food Res.** 2016;60(4):685–98. doi:10.1002/mnfr.201500593.

12. Messina M. Soy and health update: Evaluation of the clinical and epidemiologic literature. **Nutrients.** 2016;8(12):754. doi:10.3390/nu8120754.
13. Shukla Y, Singh R. Resveratrol and cellular mechanisms of cancer prevention. **Ann N Y Acad Sci.** 2011;1215:1–8. doi:10.1111/j.1749-6632.2010.05845.x.
14. Ko JH, Sethi G, Um JY, Shanmugam MK, Arfuso F, Kumar AP, et al. The role of resveratrol in cancer therapy. **Int J Mol Sci.** 2017;18(12):2589. doi:10.3390/ijms18122589.
15. Tillhon M, Guaman Ortiz LM, Lombardi P, Scovassi AI. Berberine: New perspectives for old remedies. **Biochem Pharmacol.** 2012;84(10):1260–7. doi:10.1016/j.bcp.2012.07.018.
16. Liu Y, Liu X, Zhang N, Yin M, Dong J, Zeng Q, et al. Berberine inhibits proliferation and induces apoptosis in breast cancer cells by suppressing Akt signaling. **Mol Med Rep.** 2016;13(4):3947–53. doi:10.3892/mmr.2016.5034.
17. Amin A, Kucuk O, Khuri FR, Shin DM. Perspectives for cancer prevention with natural compounds. **J Clin Oncol.** 2009;27(16):2712–25. doi:10.1200/JCO.2008.20.6235.
18. Greenwell M, Rahman PKSM. Medicinal plants: Their use in anticancer treatment. **Int J Pharm Sci Res.** 2015;6(10):4103–12.

How to cite this article:
Akshay Rajendra Kundale et al. Ijppr.Human, 2026; Vol. 32 (2): 283-298.

Conflict of Interest Statement: All authors have nothing else to disclose.